Table 1.
Study |
HbA1c |
Outcome of albuminuria or renal events | |
Intensive treatment | Conventional treatment | ||
ACCORD[45] | 6.4% vs 7.6% | 21% ↓ in onset of microalbuminuria | |
32% ↓ in progression to macroalbuminuria | |||
ADVANCE[46] | 6.5% vs 7.3% | 9% ↓ in onset of microalbuminuria | |
30% ↓ in progression to macroalbuminuria | |||
21% ↓ in renal events | |||
New onset macroalbuminuria | |||
Doubling of serum Cr | |||
Kidney replacement therapy | |||
Death due to kidney disease | |||
VADT[47] | 6.9% vs 8.4% | 32% ↓ in progression from normal to microalbuminuria or macroalbuminuria | |
37% ↓ in progression from normal to microalbuminuria to macroalbuminuria | |||
34% ↓ in any increase in albuminuria |
ACCORD: Action to Control Cardiovascular Risk in Diabetes; ADVANCE: Action in Diabetes and Vascular disease: Preterax and Diamicron MR Controlled Evaluation; VADT: Veterans Affairs Diabetes Trial.